What sector does Abbott Laboratories belong to?

Abbott Laboratories operates in the Health Care sector, specifically the Health Care Equipment industry, and is listed on the US markets.

What is the current share price of ABT?

As of the latest available quote, ABT traded at $101.95. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of ABT?

Abbott Laboratories has a price-to-earnings (P/E) ratio of about 32.99. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of ABT?

The market capitalisation of Abbott Laboratories is approximately $178.80B.

Is Abbott Laboratories profitable?

For its latest reported financial year, Abbott Laboratories recorded a net profit margin of about 14.72%.

Does ABT pay a dividend?

Abbott Laboratories currently has a dividend yield of about 2.40%.

What is the return on equity (ROE) of ABT?

Abbott Laboratories has a return on equity (ROE) of about 12.53%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of ABT?

Over the past 52 weeks, ABT has traded between a low of $81.97 and a high of $137.49.

Abbott Laboratories

ABT US Health Care Health Care Equipment

S&P 500

$101.95

-1.36%

Delayed · cached 15 min

Fair value analysis

ABT

Abbott Laboratories

$101.95

Close used for this calculation

$72.56Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

54/100

Profitability15/25

Returns7/25

Balance Sheet21/25

Efficiency11/25

Growth6/25

Good

Quality radar

Consensus fair value

$72.56

Above FV

▼ -28.8% against the close used

Model range $32.25 – $129.37

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear$32.25Fair value$72.56Bull$129.37

FairClose

52-week traded range

52W low $82.5652W high $136.62

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

Abbott Laboratories closed at $101.95, 40.5% above the consensus fair value of $72.56 drawn from 9 valuation models.

Financial DNA score 54/100 — Good. P/E of 27.4x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

$82.13

-19.4%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=8.7%, r=10%, tg=3%, n=10yr

Graham Number

$49.95

-51.0%

√(22.5 × EPS × BVPS)

EPS=3.72, BVPS=29.81 · outside Graham range (P/E 27.4, P/B 3.4) — asset-light, treat as a rough floor

P/E Fair Value

$74.40

-27.0%

EPS × 20x (sector P/E)

EPS=3.72, Sector P/E=20x

Peter Lynch (PEG)

$32.25

-68.4%

EPS × Growth% (PEG = 1 is fair)

EPS=3.72, g=8.7%

EV/EBITDA

$75.03

-26.4%

(EBITDA × 14.3x − Net Debt) ÷ Shares

EBITDA=9.49B

Dividend Discount (DDM)

$129.37

+26.9%

D1 ÷ (r − g) where D1 = D0×(1+g)

D0=2.4, r=10%, g=8%

Book Value (P/B)

$48.66

-52.3%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=29.81, ROE=12.5%, g=6%, r=10%

Reverse DCF

$101.95

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 11.4% | Historical: 8.7%

Margin of Safety

$51.62

-49.4%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=68.83, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer